New: NCI-funded clinical trial search
Mednet Logo

Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?

Patient with extrahepatic cholangiocarcinoma s/p Whipple in 2021 with negative margins and no positive nodes followed by adjuvant chemo with subsequent recurrence in the right hepatic lobe in 2024 now s/p Y 90 radioembolization with further disease progression of the single metastatic site now 8.3 cm in size.
Community PollStarted

For patient with an isolated but large liver metastasis, what would be your recommendation, assuming patient can tolerate all treatments but disease is unresectable?

312 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on

Challenging case and worthy of tumor board discussion. I would likely start systemic therapy, and if response, consider regional therapy with resection or SBRT, assuming the hepatic function is adequate (keep in mind, TARE can cause liver disease). I have one patient in a similar situation, now > 5 years out and NED after resection of initially unresectable cholangio. Ablative procedures such as repeat catheter-based therapy and even SBRT have a risk of hepatic abscess after the Whipple procedure, given the hepaticojejunostomy. Can be done but has to be done carefully...

Join for free or sign in to see the full answer

Mednet Member
Radiation Oncology · University of Illinois College of Medicine
Answered on

Considering post-TARE dosimetry using PET imaging to see the dose to the tumor and uninvolved liver, there are several software programs doing this, including MIM. Often, TARE delivers a non-uniform dose to the large liver tumor. One then generates a treatment plan for proton (or carbon, not available in the US as of now) beam therapy, preferably IMPT, depending on the underlying liver reserve (Child-Pugh score) and tumor location, one can deliver a reasonable dose to the active tumor area while sparing the uninvolved liver. Use NRG GI-003 for set-up and planning.

Oshiro et al., PMID 28366501

Join for free or sign in to see the full answer